p62 as a therapeutic target for inhibition of autophagy in prostate cancer.
| Author | |
|---|---|
| Abstract |
:
To test the hypothesis that p62 is an optimal target for autophagy inhibition and Verteporfin, a clinically available drug approved by FDA to treat macular degeneration that inhibits autophagy by targeting p62 protein, can be developed clinically to improve therapy for advanced prostate cancer. |
| Year of Publication |
:
2018
|
| Journal |
:
The Prostate
|
| Date Published |
:
2018
|
| ISSN Number |
:
0270-4137
|
| DOI |
:
10.1002/pros.23483
|
| Short Title |
:
Prostate
|
| Download citation |
